The outcomes of gene as well as protein level expression studies using scRNA-Seq, cell lines, and tumor tissues derived from human and spontaneous SCLC mouse model suggest that SCLC cells showed substantially higher expression of FOXM1 compared to normal lung and/or LUAD, indicating that FOXM1 is a key TF for SCLC that could be evaluated for targeted therapies. The gene discussed is FOXM1; the disease is small cell lung carcinoma.